LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
Enrolling by invitation · NCT06876675 · Registry updated 2025-03-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer | Dyslipidemias, Lipid Metabolism Disorders, Neoplasms by Site, Nutritional and Metabolic Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, hyperlipidemia, lung disorder, lung neoplasm, metabolic disease, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Enrolling by invitation | Not stated | 2025-03-14 | NCT06876675 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University Third Hospital | 243 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University Third Hospital | Beijing | China | 71 |